The emergence of GLP-1 receptor agonists like semaglutide and tirzepatide has revolutionized the approach to treating type 2 diabetes and supporting weight reduction. While both drugs share a shared mechanism of action – mimicking the effects of the natural hormone GLP-1 – tirzepatide possesses a distinct advantage: it’s a dual activator, tar